Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776087 | 1.00 | ROCK2 (0.42) | ROCK2ROCK1HSD17B2CHRNB4CHRNA3 | |
| SCHEMBL4795682 | 0.85 | ROCK2 (0.40) | ROCK2ROCK1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL4777518 | 0.82 | SCN9A (0.41) | — | |
| SCHEMBL4776201 | 0.82 | ROCK2 (0.42) | ROCK2ROCK1HSD17B2 | |
| SCHEMBL4776197 | 0.82 | ROCK2 (0.42) | ROCK2ROCK1HSD17B2 | |
| SCHEMBL8222692 | 0.82 | SCN9A (0.41) | — | |
| SCHEMBL8221589 | 0.79 | GPR119 (0.43) | — | |
| SCHEMBL8222689 | 0.78 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL4725436 | 0.78 | CHRNB4 (0.46) | HSD17B2CHRNB4CHRNA3 | |
| SCHEMBL4725442 | 0.78 | CHRNB4 (0.46) | HSD17B2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |